2025.05. 24 本文字数：2099，阅读时长大约3分钟 Wind数据显示，在已经披露2024年年报的药企中，高管年薪在千万以上绝非个例。在俞德超之前， 还有多家药企的高管薪酬过亿。 作者 | 第一财经 陈敏之 近日，理想汽车（02015.HK/LI.US）创始人、董事长兼CEO李想2024年领取6.39亿元"天价年薪"冲 上热搜引发热议。 事实上，创新药企业里，也不乏上亿年薪的创始人和CEO，但有所不同的是，这些创新药公司多数 还没有走完商业化历程，公司处于连年亏损状态。比如刚刚敲钟上市的映恩生物（9606.HK），创 始人朱忠远去年薪酬8556万元，公司同期亏损超过10亿元。近期三次递表港交所的英矽智能，执行 董事任峰2024年薪酬总计307.3万美元，公司当年净亏损1709.6万美元。 这样例子在创新药企业里比比皆是。Wind数据显示，思路迪医药股份（1244.HK）董事长龚兆龙 2024年的薪酬为2067万元，六年的薪酬总额则超过5亿元，而公司六年亏损超40亿元。 高薪背后，是创新药行业整体尚未步出资本寒冬。高管的收入与公司业绩形成的强烈反差，引发市场 对行业价值导向的深度思考。 年薪千万比比皆 ...

Group 1 - The article highlights the stark contrast between high executive salaries and the financial performance of companies in the innovative drug sector, where many firms are still unprofitable [2][10][11] - Li Xiang, the founder and CEO of Li Auto, received a salary of 639 million RMB in 2024, sparking discussions about excessive executive compensation in the context of ongoing company losses [2][3] - Companies like InnoCare Pharma and Sihuan Pharmaceutical have reported significant executive salaries while simultaneously posting substantial losses, raising questions about the sustainability of such compensation structures [5][10] Group 2 - The article provides examples of high executive salaries in the innovative drug industry, including Zhu Zhongyuan of InnoCare Pharma with a salary of 85.56 million RMB in 2024, despite the company losing over 1 billion RMB [3][10] - Other notable salaries include Yu Dechao of Innovent Biologics, who earned approximately 136 million RMB, and Gong Zhaolong of Sihuan Pharmaceutical, whose total compensation exceeded 500 million RMB over six years [5][10] - The trend of high salaries persists even among companies that have not yet commercialized their products, such as Yingxi Intelligent and Weili Zhibo, which have reported significant losses [11]